Fig. 1
From: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
ORF kinome screen identifies drivers of resistance to fulvestrant ± CDK4/6 inhibitors. a, b ORF kinome screen in MCF-7 cells treated with fulvestrant (a) or fulvestrant plus ribociclib (b). ORFs are visualized by plotting the function y = z-score, x = gene name. Data points represent the average of two replicate plates. c Modified Venn diagram of screening results showing the number of fulvestrant hits (left) or fulvestrant plus ribociclib hits (right). d Heat map displaying validation results of the hits selected in the fulvestrant plus ribociclib screen. Top and bottom row show the normalized area under the curve (AUC) for each candidate genes with 5-point drug concentration, fulvestrant plus palbociclib (top row) and fulvestrant plus ribociclib (bottom row). GFP and mutant MEKS218/222D (MEK-DD) were used as internal controls
